Shilpa Medicare Limited

NSEI:SHILPAMED Stok Raporu

Piyasa değeri: ₹77.5b

Shilpa Medicare Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Shilpa Medicare kazanç ve gelirin sırasıyla yıllık 77.1% ve 29.2% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 76.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 14.1% olacağı tahmin edilmektedir.

Anahtar bilgiler

77.1%

Kazanç büyüme oranı

76.5%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi17.9%
Gelir büyüme oranı29.2%
Gelecekteki özkaynak getirisi14.1%
Analist kapsamı

Low

Son güncelleme18 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

What Shilpa Medicare Limited's (NSE:SHILPAMED) 28% Share Price Gain Is Not Telling You

Sep 12
What Shilpa Medicare Limited's (NSE:SHILPAMED) 28% Share Price Gain Is Not Telling You

Shilpa Medicare Limited's (NSE:SHILPAMED) 29% Price Boost Is Out Of Tune With Revenues

Jul 05
Shilpa Medicare Limited's (NSE:SHILPAMED) 29% Price Boost Is Out Of Tune With Revenues

What Shilpa Medicare Limited's (NSE:SHILPAMED) 27% Share Price Gain Is Not Telling You

Apr 12
What Shilpa Medicare Limited's (NSE:SHILPAMED) 27% Share Price Gain Is Not Telling You

Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up

Feb 21
Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up

Shilpa Medicare (NSE:SHILPAMED) Takes On Some Risk With Its Use Of Debt

Jan 02
Shilpa Medicare (NSE:SHILPAMED) Takes On Some Risk With Its Use Of Debt

These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Extensively

Jul 17
These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Extensively

Shilpa Medicare (NSE:SHILPAMED) Seems To Be Using A Lot Of Debt

Mar 17
Shilpa Medicare (NSE:SHILPAMED) Seems To Be Using A Lot Of Debt

Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)

Sep 22
Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)

Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Sep 07
Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Aug 14
Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Here's Why Shilpa Medicare (NSE:SHILPAMED) Is Weighed Down By Its Debt Load

Jan 27
Here's Why Shilpa Medicare (NSE:SHILPAMED) Is Weighed Down By Its Debt Load

Shareholders May Not Be So Generous With Shilpa Medicare Limited's (NSE:SHILPAMED) CEO Compensation And Here's Why

Sep 21
Shareholders May Not Be So Generous With Shilpa Medicare Limited's (NSE:SHILPAMED) CEO Compensation And Here's Why

Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

Jun 17
Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

If You Like EPS Growth Then Check Out Shilpa Medicare (NSE:SHILPAMED) Before It's Too Late

May 31
If You Like EPS Growth Then Check Out Shilpa Medicare (NSE:SHILPAMED) Before It's Too Late

Shilpa Medicare Limited's (NSE:SHILPAMED) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Mar 07
Shilpa Medicare Limited's (NSE:SHILPAMED) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Shilpa Medicare Limited (NSE:SHILPAMED) Analysts Are Reducing Their Forecasts For Next Year

Feb 20
Shilpa Medicare Limited (NSE:SHILPAMED) Analysts Are Reducing Their Forecasts For Next Year

Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

Jan 26
Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

Kazanç ve Gelir Büyüme Tahminleri

NSEI:SHILPAMED - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
3/31/202726,7206,215N/A5,7261
3/31/202617,0943,648N/A3,5052
3/31/202514,4131,3403542,7041
9/30/202412,163611-4521,500N/A
6/30/202411,839448N/AN/AN/A
3/31/202411,531319-4921,353N/A
12/31/202311,248-7N/AN/AN/A
9/30/202311,008-119-302,523N/A
6/30/202310,491-321N/AN/AN/A
3/31/202310,517-325-4671,799N/A
12/31/202211,28651N/AN/AN/A
9/30/202211,384213-1,6201,651N/A
6/30/202211,693599N/AN/AN/A
3/31/202211,469607-2,2671,051N/A
12/31/202110,135395N/AN/AN/A
9/30/20219,324376-2,589478N/A
6/30/20219,156631N/AN/AN/A
3/31/20219,0161,478-3,073469N/A
12/31/20209,1351,739N/AN/AN/A
9/30/20209,5912,213-2,704793N/A
6/30/20209,6982,267N/AN/AN/A
3/31/20209,0821,562-2,2491,244N/A
12/31/20198,8761,455N/AN/AN/A
9/30/20198,2411,029-3,065819N/A
6/30/20196,962944N/AN/AN/A
3/31/20197,3371,123-1,5321,468N/A
12/31/20187,6931,193N/AN/AN/A
9/30/20187,8141,281N/AN/AN/A
6/30/20188,2111,167N/AN/AN/A
3/31/20187,8941,052N/A449N/A
12/31/20177,7561,133N/AN/AN/A
9/30/20177,7311,149N/AN/AN/A
6/30/20177,7871,190N/AN/AN/A
3/31/20177,7951,076N/A375N/A
12/31/20167,5651,048N/AN/AN/A
9/30/20167,7351,153N/AN/AN/A
6/30/20167,3691,024N/AN/AN/A
3/31/20167,1661,083N/A1,287N/A
12/31/20156,867886N/AN/AN/A
9/30/20156,430776N/AN/AN/A
6/30/20156,234728N/AN/AN/A
3/31/20156,138737N/A688N/A
12/31/20146,145731N/AN/AN/A
9/30/20146,143798N/AN/AN/A
6/30/20145,966787N/AN/AN/A
3/31/20145,714757N/A700N/A
12/31/20135,025664N/AN/AN/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: SHILPAMED 'nin tahmini kazanç büyümesi (yıllık 77.1% ) tasarruf oranının ( 6.7% ) üzerindedir.

Kazançlar ve Piyasa: SHILPAMED şirketinin kazançlarının (yıllık 77.1% ) Indian pazarından (yıllık 17.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: SHILPAMED şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: SHILPAMED şirketinin gelirinin (yıllık 29.2% ) Indian pazarından (yıllık 10.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: SHILPAMED şirketinin gelirinin (yıllık 29.2% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: SHILPAMED 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 14.1 %).


Büyüyen şirketleri keşfedin